Skip to main content
Clinical Trials/NCT02538029
NCT02538029
Completed
Not Applicable

The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease

The Cleveland Clinic1 site in 1 country45 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson's Disease
Sponsor
The Cleveland Clinic
Enrollment
45
Locations
1
Primary Endpoint
Step Length During Gait
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The primary aim of the proposed project is to characterize dual tasking (DT) deficits to improve motor, cognitive, and quality of life outcomes in individuals with Parkinson's disease (PD). Phase 1 of the intervention will involve an in-depth gait analysis on 15 individuals with PD. This gait analysis will utilize the Computer Assisted Rehabilitation Environment (CAREN) system, a virtual reality system with a fully integrated 3-D motion capture system. The purpose of Phase 1 is to generalize characteristics of gait and postural control during specific DT conditions. Phase 2 (N=20) involves the clinical translation of these findings. This phase will involve creating a clinical intervention based on the objective information gathered the CAREN system. The intervention will take place 3x/week for a total of 8 weeks. Interventional groups will include: 1) DT clinical group (N=10) and 2) Single task group (N=10). Outcome measures will be used at the beginning and end of the intervention to assess the feasibility and efficacy of the intervention.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
August 16, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jay Alberts

Staff

The Cleveland Clinic

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of idiopathic PD
  • Able to provide informed consent
  • Ability to ambulate ≥ 300ft with or without an assistive device
  • Hoehn and Yahr stage 2-4

Exclusion Criteria

  • Undergone any surgical procedure for the treatment of PD, such as deep brain stimulation
  • Those who are considered to be high risk exercisers per American College of Sports Medicine exercise screening questionnaire
  • Musculoskeletal injury or neurological injury other than PD that would restrict physical activity
  • Inability to follow 2 step commands
  • Significant cognitive impairment as designated by ≥ 3 errors on the Short Portable Mental Status Questionnaire

Outcomes

Primary Outcomes

Step Length During Gait

Time Frame: Phase 1: baseline; Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks

The average distance from heel strike of the less affected leg to heel strike of the more affected leg. Higher values indicate a longer step length.

Walking Speed During Gait

Time Frame: Phase 1: baseline; Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks

Average self-selected walking speed without dual tasking.

Secondary Outcomes

  • 2 Minute Walk Test(Phase 1: baseline; Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks)
  • Trail Making Test(Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks)
  • Quality of Life in Neurological Disorders Questionnaire(Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks)
  • Activities-specific Balance Confidence Scale(Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks)
  • Reaction Time(Phase 2: baseline, end of treatment (8 weeks), and end of treatment +4 weeks)

Study Sites (1)

Loading locations...

Similar Trials